Wire · opportunities
SRD-002 Gene Therapy Shows Sustained HFpEF Improvement at 12 Months
◆ Sectors
Biotech
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
SRD-002, a gene therapy using AAV1 to deliver SERCA2a, showed a 30% reduction in peak exercise pulmonary capillary wedge pressure and 80% normalization in 10 HFpEF patients at 12 months, suggesting durable improvement from a single dose.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your heart failure biotech project must track durability data beyond 12 months closely as a single-shot gene therapy showing sustained effect could reset treatment standards in HFpEF and open regulator paths for intermediate endpoint approval.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics
Biotechhfpefgene-therapycardiologyclinical-trialdurability